Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
DigitalOcean Holdings' Q3 Non-GAAP Earnings Decline, Revenue Increases; 2026 Outlook Raised

DigitalOcean Holdings' Q3 Non-GAAP Earnings Decline, Revenue Increases; 2026 Outlook Raised

MT newswireMT newswire2026/11/03 11:32
07:32 AM EST, 11/03/2026 (MT Newswires) -- DigitalOcean Holdings (DOCN) reported Q3 non-GAAP earnings Tuesday of $0.45 per diluted share, down from $0.54 a year earlier. Analysts polled by FactSet expected $0.32. Revenue for the quarter ended Sept. 30 was $321.2 million, compared with $229.6 million a year earlier. Analysts expected $306.7 million. The company expects Q4 non-GAAP earnings of $0.30 to $0.32 on revenue of $348 million to $351 million. Analysts expect $0.27 in non-GAAP EPS on revenue of $333.4 million. For 2026, DigitalOcean raised its outlook to 1.60 to $1.62 in non-GAAP EPS on revenue of $1.208 billion to $1.211 billion. The company previously projected $1.35 to $1.40 in non-GAAP EPS and $1.17 billion to $1.18 billion in revenue. Analysts expect $1.46 in non-GAAP EPS on revenue of $1.18 billion.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss